secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001654954-24-013720
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences announces 1-for-35 reverse stock split effective Nov 7, 2024
--------------------------------------------------------------------------------

- Board approved a ratio of 1/35 for the reverse stock split authorized by stockholders on Oct 28, 2024.
- Amendment to Certificate of Incorporation filed with Delaware Secretary of State on Nov 4, 2024, effective 12:01 a.m. ET on Nov 7, 2024.
- Common stock will trade on split-adjusted basis under new CUSIP 29273B 500 beginning Nov 7, 2024.
- Each issued share of common stock will be reclassified and converted into 1/35 of a share.
- No change to the par value of $0.0001 per share or the authorized number of shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424013720/0001654954-24-013720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424013720/endra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-013720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer